|
Date
|
Update
|
|
28 May 2020
|
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy ID1684. We have recently invited stakeholders to respond to a written consultation on the draft scope.
On receiving updated regulatory timing information from the company that is developing axicabtagene ciloleucel, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently, the consultation on the draft scope will be closed. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.
If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)
|
|
24 January 2020
|
In progress. Topic is in progress |